The FDA clearance and rapid enrollment de-risk the ADAPT trial and support a path to Phase 3. With an $8M market cap and no near-term financing need, this is a positive catalyst. Monitor for completion of enrollment and any partnership or licensing interest. The stock may re-rate on Phase 3 preparation news.
Price Chart
Executive Summary
Creative Medical Technology announced FDA clearance to expand its ADAPT Phase 2 trial of CELZ-201 (Olastrocel) for chronic lower back pain, adding a 15-patient cohort of moderate opioid users. The expansion cohort is already >85% enrolled, and the company plans to use the data to support Phase 3 discussions with the FDA. This is a positive clinical milestone for a small-cap biotech with an $8M market cap, but the stock impact is tempered by the early-stage nature and lack of financial data.
Key Facts
- FDA cleared expansion of ADAPT trial for CELZ-201 (Olastrocel) in chronic lower back pain.
- Expansion cohort adds 15 patients receiving <90 mg morphine equivalents per day.
- Expansion cohort is already >85% enrolled; completion expected before end of summer 2026.
- Original ADAPT cohort completed enrollment in December 2025 with positive interim 180-day data.
- Company expects to fund expansion with existing resources; no additional capital raise mentioned.
- Company plans to initiate Phase 3 discussions with FDA using expanded dataset.
Financial Impact
No financial figures provided; company expects to fund expansion with existing resources.
Risk Factors
- Clinical-stage biotech with no approved products or revenue; high execution risk.
- Phase 3 discussions may not lead to pivotal trial design or regulatory success.
- Small market cap and low liquidity could amplify volatility on any news.
- Competition from existing and pipeline chronic pain treatments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315350 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | SC 13D | $0.9464 $0.9200 | ▼ −2.79% | ▼ −3.46% | $0.6900 (−27.09%) |
Sep 25, 2026 4w ago | 8-K | $1.01 $0.9652 | ▼ −4.44% | ▼ −4.25% | $0.6900 (−31.68%) |
Sep 17, 2026 5w ago | Press Release | $0.8775 $0.9659 | ▲ +10.07% | ▲ +10.19% | $0.6900 (−21.37%) |
Aug 20, 2026 9w ago | Press Release | $1.28 $1.31 | ▲ +2.34% | ▲ +1.93% | $0.6900 (−46.09%) |
Jul 1, 2026 16w ago | Press Release | $1.27 $1.21 | ▼ −4.72% | ▼ −4.59% | $0.6900 (−45.67%) |
Jun 30, 2026 16w ago | Press Release | $1.45 $1.27 | ▲ +12.41% | ▲ +12.28% | $0.6900 (+52.41%) |
Jun 26, 2026 17w ago | S-1/A | $0.8102 $1.45 | ▼ −78.97% | ▼ −78.19% | $0.6900 (+14.84%) |
Jun 25, 2026 17w ago | S-1 | $1.20 $0.8102 | ▼ −32.48% | ▼ −34.13% | $0.6900 (−42.50%) |
Jun 22, 2026 18w ago | Press Release | $1.93 $1.97 | ▲ +2.07% | ▲ +3.52% | $0.6900 (−64.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers